TargetTyrosine-protein phosphatase non-receptor type 11(Homo sapiens (Human))
Revolution Medicines
US Patent
Revolution Medicines
US Patent
Affinity DataIC50: 1nMAssay Description:The inhibition of SHP2 by compounds of the invention (concentrations varying from 0.00005-10 μM) was monitored using an assay in which 0.2 nM of...More data for this Ligand-Target Pair
TargetTyrosine-protein phosphatase non-receptor type 11(Homo sapiens (Human))
Revolution Medicines
US Patent
Revolution Medicines
US Patent
Affinity DataIC50: 10nMAssay Description:The inhibition of SHP2 by compounds of the invention (concentrations varying from 0.00005-10 μM) was monitored using an assay in which 0.2 nM of...More data for this Ligand-Target Pair
TargetTyrosine-protein phosphatase non-receptor type 11(Homo sapiens (Human))
Revolution Medicines
US Patent
Revolution Medicines
US Patent
Affinity DataIC50: 29nMAssay Description:The inhibition of SHP2 by compounds of the invention (concentrations varying from 0.00005-10 μM) was monitored using an assay in which 0.2 nM of...More data for this Ligand-Target Pair
TargetTyrosine-protein phosphatase non-receptor type 11(Homo sapiens (Human))
Revolution Medicines
US Patent
Revolution Medicines
US Patent
Affinity DataIC50: <50nMAssay Description:The inhibition of SHP2 by compounds of the invention (concentrations varying from 0.00005-10 μM) was monitored using an assay in which 0.2 nM of...More data for this Ligand-Target Pair
TargetTyrosine-protein phosphatase non-receptor type 11(Homo sapiens (Human))
Revolution Medicines
US Patent
Revolution Medicines
US Patent
Affinity DataIC50: <50nMAssay Description:The inhibition of SHP2 by compounds of the invention (concentrations varying from 0.00005-10 μM) was monitored using an assay in which 0.2 nM of...More data for this Ligand-Target Pair
TargetTyrosine-protein phosphatase non-receptor type 11(Homo sapiens (Human))
Revolution Medicines
US Patent
Revolution Medicines
US Patent
Affinity DataIC50: <50nMAssay Description:The inhibition of SHP2 by compounds of the invention (concentrations varying from 0.00005-10 μM) was monitored using an assay in which 0.2 nM of...More data for this Ligand-Target Pair
TargetTyrosine-protein phosphatase non-receptor type 11(Homo sapiens (Human))
Revolution Medicines
US Patent
Revolution Medicines
US Patent
Affinity DataIC50: <50nMAssay Description:The inhibition of SHP2 by compounds of the invention (concentrations varying from 0.00005-10 μM) was monitored using an assay in which 0.2 nM of...More data for this Ligand-Target Pair
TargetTyrosine-protein phosphatase non-receptor type 11(Homo sapiens (Human))
Revolution Medicines
US Patent
Revolution Medicines
US Patent
Affinity DataIC50: <50nMAssay Description:The inhibition of SHP2 by compounds of the invention (concentrations varying from 0.00005-10 μM) was monitored using an assay in which 0.2 nM of...More data for this Ligand-Target Pair
TargetTyrosine-protein phosphatase non-receptor type 11(Homo sapiens (Human))
Revolution Medicines
US Patent
Revolution Medicines
US Patent
Affinity DataIC50: <50nMAssay Description:The inhibition of SHP2 by compounds of the invention (concentrations varying from 0.00005-10 μM) was monitored using an assay in which 0.2 nM of...More data for this Ligand-Target Pair
TargetTyrosine-protein phosphatase non-receptor type 11(Homo sapiens (Human))
Revolution Medicines
US Patent
Revolution Medicines
US Patent
Affinity DataIC50: <50nMAssay Description:The inhibition of SHP2 by compounds of the invention (concentrations varying from 0.00005-10 μM) was monitored using an assay in which 0.2 nM of...More data for this Ligand-Target Pair
TargetTyrosine-protein phosphatase non-receptor type 11(Homo sapiens (Human))
Revolution Medicines
US Patent
Revolution Medicines
US Patent
Affinity DataIC50: <50nMAssay Description:The inhibition of SHP2 by compounds of the invention (concentrations varying from 0.00005-10 μM) was monitored using an assay in which 0.2 nM of...More data for this Ligand-Target Pair
TargetTyrosine-protein phosphatase non-receptor type 11(Homo sapiens (Human))
Revolution Medicines
US Patent
Revolution Medicines
US Patent
Affinity DataIC50: <50nMAssay Description:The inhibition of SHP2 by compounds of the invention (concentrations varying from 0.00005-10 μM) was monitored using an assay in which 0.2 nM of...More data for this Ligand-Target Pair
TargetTyrosine-protein phosphatase non-receptor type 11(Homo sapiens (Human))
Revolution Medicines
US Patent
Revolution Medicines
US Patent
Affinity DataIC50: <50nMAssay Description:The inhibition of SHP2 by compounds of the invention (concentrations varying from 0.00005-10 μM) was monitored using an assay in which 0.2 nM of...More data for this Ligand-Target Pair
TargetTyrosine-protein phosphatase non-receptor type 11(Homo sapiens (Human))
Revolution Medicines
US Patent
Revolution Medicines
US Patent
Affinity DataIC50: <50nMAssay Description:The inhibition of SHP2 by compounds of the invention (concentrations varying from 0.00005-10 μM) was monitored using an assay in which 0.2 nM of...More data for this Ligand-Target Pair
TargetTyrosine-protein phosphatase non-receptor type 11(Homo sapiens (Human))
Revolution Medicines
US Patent
Revolution Medicines
US Patent
Affinity DataIC50: <50nMAssay Description:The inhibition of SHP2 by compounds of the invention (concentrations varying from 0.00005-10 μM) was monitored using an assay in which 0.2 nM of...More data for this Ligand-Target Pair
TargetTyrosine-protein phosphatase non-receptor type 11(Homo sapiens (Human))
Revolution Medicines
US Patent
Revolution Medicines
US Patent
Affinity DataIC50: <50nMAssay Description:The inhibition of SHP2 by compounds of the invention (concentrations varying from 0.00005-10 μM) was monitored using an assay in which 0.2 nM of...More data for this Ligand-Target Pair
TargetTyrosine-protein phosphatase non-receptor type 11(Homo sapiens (Human))
Revolution Medicines
US Patent
Revolution Medicines
US Patent
Affinity DataIC50: <50nMAssay Description:The inhibition of SHP2 by compounds of the invention (concentrations varying from 0.00005-10 μM) was monitored using an assay in which 0.2 nM of...More data for this Ligand-Target Pair
TargetTyrosine-protein phosphatase non-receptor type 11(Homo sapiens (Human))
Revolution Medicines
US Patent
Revolution Medicines
US Patent
Affinity DataIC50: <50nMAssay Description:The inhibition of SHP2 by compounds of the invention (concentrations varying from 0.00005-10 μM) was monitored using an assay in which 0.2 nM of...More data for this Ligand-Target Pair
TargetTyrosine-protein phosphatase non-receptor type 11(Homo sapiens (Human))
Revolution Medicines
US Patent
Revolution Medicines
US Patent
Affinity DataIC50: <50nMAssay Description:The inhibition of SHP2 by compounds of the invention (concentrations varying from 0.00005-10 μM) was monitored using an assay in which 0.2 nM of...More data for this Ligand-Target Pair
TargetTyrosine-protein phosphatase non-receptor type 11(Homo sapiens (Human))
Revolution Medicines
US Patent
Revolution Medicines
US Patent
Affinity DataIC50: <50nMAssay Description:The inhibition of SHP2 by compounds of the invention (concentrations varying from 0.00005-10 μM) was monitored using an assay in which 0.2 nM of...More data for this Ligand-Target Pair
TargetTyrosine-protein phosphatase non-receptor type 11(Homo sapiens (Human))
Revolution Medicines
US Patent
Revolution Medicines
US Patent
Affinity DataIC50: <50nMAssay Description:The inhibition of SHP2 by compounds of the invention (concentrations varying from 0.00005-10 μM) was monitored using an assay in which 0.2 nM of...More data for this Ligand-Target Pair
TargetTyrosine-protein phosphatase non-receptor type 11(Homo sapiens (Human))
Revolution Medicines
US Patent
Revolution Medicines
US Patent
Affinity DataIC50: <50nMAssay Description:The inhibition of SHP2 by compounds of the invention (concentrations varying from 0.00005-10 μM) was monitored using an assay in which 0.2 nM of...More data for this Ligand-Target Pair
TargetTyrosine-protein phosphatase non-receptor type 11(Homo sapiens (Human))
Revolution Medicines
US Patent
Revolution Medicines
US Patent
Affinity DataIC50: <50nMAssay Description:The inhibition of SHP2 by compounds of the invention (concentrations varying from 0.00005-10 μM) was monitored using an assay in which 0.2 nM of...More data for this Ligand-Target Pair
TargetTyrosine-protein phosphatase non-receptor type 11(Homo sapiens (Human))
Revolution Medicines
US Patent
Revolution Medicines
US Patent
Affinity DataIC50: <50nMAssay Description:The inhibition of SHP2 by compounds of the invention (concentrations varying from 0.00005-10 μM) was monitored using an assay in which 0.2 nM of...More data for this Ligand-Target Pair
TargetTyrosine-protein phosphatase non-receptor type 11(Homo sapiens (Human))
Revolution Medicines
US Patent
Revolution Medicines
US Patent
Affinity DataIC50: <50nMAssay Description:The inhibition of SHP2 by compounds of the invention (concentrations varying from 0.00005-10 μM) was monitored using an assay in which 0.2 nM of...More data for this Ligand-Target Pair
TargetTyrosine-protein phosphatase non-receptor type 11(Homo sapiens (Human))
Revolution Medicines
US Patent
Revolution Medicines
US Patent
Affinity DataIC50: <50nMAssay Description:The inhibition of SHP2 by compounds of the invention (concentrations varying from 0.00005-10 μM) was monitored using an assay in which 0.2 nM of...More data for this Ligand-Target Pair
TargetTyrosine-protein phosphatase non-receptor type 11(Homo sapiens (Human))
Revolution Medicines
US Patent
Revolution Medicines
US Patent
Affinity DataIC50: <50nMAssay Description:The inhibition of SHP2 by compounds of the invention (concentrations varying from 0.00005-10 μM) was monitored using an assay in which 0.2 nM of...More data for this Ligand-Target Pair
TargetTyrosine-protein phosphatase non-receptor type 11(Homo sapiens (Human))
Revolution Medicines
US Patent
Revolution Medicines
US Patent
Affinity DataIC50: <50nMAssay Description:The inhibition of SHP2 by compounds of the invention (concentrations varying from 0.00005-10 μM) was monitored using an assay in which 0.2 nM of...More data for this Ligand-Target Pair
TargetTyrosine-protein phosphatase non-receptor type 11(Homo sapiens (Human))
Revolution Medicines
US Patent
Revolution Medicines
US Patent
Affinity DataIC50: <50nMAssay Description:The inhibition of SHP2 by compounds of the invention (concentrations varying from 0.00005-10 μM) was monitored using an assay in which 0.2 nM of...More data for this Ligand-Target Pair
TargetTyrosine-protein phosphatase non-receptor type 11(Homo sapiens (Human))
Revolution Medicines
US Patent
Revolution Medicines
US Patent
Affinity DataIC50: <50nMAssay Description:The inhibition of SHP2 by compounds of the invention (concentrations varying from 0.00005-10 μM) was monitored using an assay in which 0.2 nM of...More data for this Ligand-Target Pair
TargetTyrosine-protein phosphatase non-receptor type 11(Homo sapiens (Human))
Revolution Medicines
US Patent
Revolution Medicines
US Patent
Affinity DataIC50: <50nMAssay Description:The inhibition of SHP2 by compounds of the invention (concentrations varying from 0.00005-10 μM) was monitored using an assay in which 0.2 nM of...More data for this Ligand-Target Pair
TargetTyrosine-protein phosphatase non-receptor type 11(Homo sapiens (Human))
Revolution Medicines
US Patent
Revolution Medicines
US Patent
Affinity DataIC50: <50nMAssay Description:The inhibition of SHP2 by compounds of the invention (concentrations varying from 0.00005-10 μM) was monitored using an assay in which 0.2 nM of...More data for this Ligand-Target Pair
TargetTyrosine-protein phosphatase non-receptor type 11(Homo sapiens (Human))
Revolution Medicines
US Patent
Revolution Medicines
US Patent
Affinity DataIC50: <50nMAssay Description:The inhibition of SHP2 by compounds of the invention (concentrations varying from 0.00005-10 μM) was monitored using an assay in which 0.2 nM of...More data for this Ligand-Target Pair
TargetTyrosine-protein phosphatase non-receptor type 11(Homo sapiens (Human))
Revolution Medicines
US Patent
Revolution Medicines
US Patent
Affinity DataIC50: <50nMAssay Description:The inhibition of SHP2 by compounds of the invention (concentrations varying from 0.00005-10 μM) was monitored using an assay in which 0.2 nM of...More data for this Ligand-Target Pair
TargetTyrosine-protein phosphatase non-receptor type 11(Homo sapiens (Human))
Revolution Medicines
US Patent
Revolution Medicines
US Patent
Affinity DataIC50: <50nMAssay Description:The inhibition of SHP2 by compounds of the invention (concentrations varying from 0.00005-10 μM) was monitored using an assay in which 0.2 nM of...More data for this Ligand-Target Pair
TargetTyrosine-protein phosphatase non-receptor type 11(Homo sapiens (Human))
Revolution Medicines
US Patent
Revolution Medicines
US Patent
Affinity DataIC50: <50nMAssay Description:The inhibition of SHP2 by compounds of the invention (concentrations varying from 0.00005-10 μM) was monitored using an assay in which 0.2 nM of...More data for this Ligand-Target Pair
TargetTyrosine-protein phosphatase non-receptor type 11(Homo sapiens (Human))
Revolution Medicines
US Patent
Revolution Medicines
US Patent
Affinity DataIC50: <50nMAssay Description:The inhibition of SHP2 by compounds of the invention (concentrations varying from 0.00005-10 μM) was monitored using an assay in which 0.2 nM of...More data for this Ligand-Target Pair
TargetTyrosine-protein phosphatase non-receptor type 11(Homo sapiens (Human))
Revolution Medicines
US Patent
Revolution Medicines
US Patent
Affinity DataIC50: <50nMAssay Description:The inhibition of SHP2 by compounds of the invention (concentrations varying from 0.00005-10 μM) was monitored using an assay in which 0.2 nM of...More data for this Ligand-Target Pair
TargetTyrosine-protein phosphatase non-receptor type 11(Homo sapiens (Human))
Revolution Medicines
US Patent
Revolution Medicines
US Patent
Affinity DataIC50: <50nMAssay Description:The inhibition of SHP2 by compounds of the invention (concentrations varying from 0.00005-10 μM) was monitored using an assay in which 0.2 nM of...More data for this Ligand-Target Pair
TargetTyrosine-protein phosphatase non-receptor type 11(Homo sapiens (Human))
Revolution Medicines
US Patent
Revolution Medicines
US Patent
Affinity DataIC50: <50nMAssay Description:The inhibition of SHP2 by compounds of the invention (concentrations varying from 0.00005-10 μM) was monitored using an assay in which 0.2 nM of...More data for this Ligand-Target Pair
TargetTyrosine-protein phosphatase non-receptor type 11(Homo sapiens (Human))
Revolution Medicines
US Patent
Revolution Medicines
US Patent
Affinity DataIC50: <50nMAssay Description:The inhibition of SHP2 by compounds of the invention (concentrations varying from 0.00005-10 μM) was monitored using an assay in which 0.2 nM of...More data for this Ligand-Target Pair
TargetTyrosine-protein phosphatase non-receptor type 11(Homo sapiens (Human))
Revolution Medicines
US Patent
Revolution Medicines
US Patent
Affinity DataIC50: <50nMAssay Description:The inhibition of SHP2 by compounds of the invention (concentrations varying from 0.00005-10 μM) was monitored using an assay in which 0.2 nM of...More data for this Ligand-Target Pair
TargetTyrosine-protein phosphatase non-receptor type 11(Homo sapiens (Human))
Revolution Medicines
US Patent
Revolution Medicines
US Patent
Affinity DataIC50: <50nMAssay Description:The inhibition of SHP2 by compounds of the invention (concentrations varying from 0.00005-10 μM) was monitored using an assay in which 0.2 nM of...More data for this Ligand-Target Pair
TargetTyrosine-protein phosphatase non-receptor type 11(Homo sapiens (Human))
Revolution Medicines
US Patent
Revolution Medicines
US Patent
Affinity DataIC50: <50nMAssay Description:The inhibition of SHP2 by compounds of the invention (concentrations varying from 0.00005-10 μM) was monitored using an assay in which 0.2 nM of...More data for this Ligand-Target Pair
TargetTyrosine-protein phosphatase non-receptor type 11(Homo sapiens (Human))
Revolution Medicines
US Patent
Revolution Medicines
US Patent
Affinity DataIC50: <50nMAssay Description:The inhibition of SHP2 by compounds of the invention (concentrations varying from 0.00005-10 μM) was monitored using an assay in which 0.2 nM of...More data for this Ligand-Target Pair
TargetTyrosine-protein phosphatase non-receptor type 11(Homo sapiens (Human))
Revolution Medicines
US Patent
Revolution Medicines
US Patent
Affinity DataIC50: <50nMAssay Description:The inhibition of SHP2 by compounds of the invention (concentrations varying from 0.00005-10 μM) was monitored using an assay in which 0.2 nM of...More data for this Ligand-Target Pair
TargetTyrosine-protein phosphatase non-receptor type 11(Homo sapiens (Human))
Revolution Medicines
US Patent
Revolution Medicines
US Patent
Affinity DataIC50: 120nMAssay Description:The inhibition of SHP2 by compounds of the invention (concentrations varying from 0.00005-10 μM) was monitored using an assay in which 0.2 nM of...More data for this Ligand-Target Pair
TargetTyrosine-protein phosphatase non-receptor type 11(Homo sapiens (Human))
Revolution Medicines
US Patent
Revolution Medicines
US Patent
Affinity DataIC50: 275nMAssay Description:The inhibition of SHP2 by compounds of the invention (concentrations varying from 0.00005-10 μM) was monitored using an assay in which 0.2 nM of...More data for this Ligand-Target Pair
TargetTyrosine-protein phosphatase non-receptor type 11(Homo sapiens (Human))
Revolution Medicines
US Patent
Revolution Medicines
US Patent
Affinity DataIC50: 275nMAssay Description:The inhibition of SHP2 by compounds of the invention (concentrations varying from 0.00005-10 μM) was monitored using an assay in which 0.2 nM of...More data for this Ligand-Target Pair
TargetTyrosine-protein phosphatase non-receptor type 11(Homo sapiens (Human))
Revolution Medicines
US Patent
Revolution Medicines
US Patent
Affinity DataIC50: 275nMAssay Description:The inhibition of SHP2 by compounds of the invention (concentrations varying from 0.00005-10 μM) was monitored using an assay in which 0.2 nM of...More data for this Ligand-Target Pair